NL-OMON27620招募中不适用
p53 synthetic long peptide vaccine with cyclofosfamide for ovarian cancer, a phase II trial
MCG0 个研究点目标入组 19 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 19
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histological proven epithelial ovarian carcinoma.
- •2. At least 4 weeks after termination of the last course of chemotherapy.
排除标准
- •1. (A)symptomatic cystitis
- •2. Other malignancies (previous or current), except basal or squamous cell carcinoma of the skin.
研究者
相似试验
已完成
2 期
p53 synthetic long peptides vaccine with cyclophosphamide for ovarian cancer, a phase II trial.ovarian carcinoma1003859410033283ovarian cancerNL-OMON31732niversitair Medisch Centrum Groningen19
进行中（未招募）
1 期
p53 synthetic long peptides vaccine with cyclophosphamide for ovarian cancer, a phase II trial. - ISA-p53-CTXEUCTR2007-007734-19-NLniversity Medical Center Groningen, UMCG-Department of Gynaecologic Oncology19
已完成
2 期
p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian CancerOvarian CancerNCT00844506University Medical Center Groningen19
招募中
不适用
p53 immunotherapy in patients treated for metastasised colorectal cancer.tumour, metastised colorectal cancerNL-OMON24376/A10
已完成
1 期
Vaccine Therapy in Treating Patients With Head and Neck CancerHead and Neck CancerNCT00404339Robert Ferris17